Home > Insider Trading > Bicara Therapeutics Inc. > Profile

Bicara Therapeutics Inc. (BCAX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Related Insiders

Lara Meisner, Chief Legal Officer, 2025-06-18
Kate Haviland, Director, 2025-06-10
Ra Capital Nexus Fund Iii, L.p., Director, 2025-06-10

Lara Meisner, Chief Legal Officer, 2025-06-18
Kate Haviland, Director, 2025-06-10
Ra Capital Nexus Fund Iii, L.p., Director, 2025-06-10
M. Rajeev Shah, Large Shareholder, Director, 2025-06-10
Peter Kolchinsky, Large Shareholder, Director, 2025-06-10
Ra Capital Management, L.p., , 2025-06-10
Ra Capital Healthcare Fund Lp, Large Shareholder, Director, 2025-06-10
Kiran Mazumdar-Shaw, Large Shareholder, Director, 2025-06-10
Michael Powell, Director, 2025-06-10
Nils Lonberg, Director, 2025-06-10
M. Scott Robertson, Director, 2025-06-10
Jake Simson, Director, 2025-06-10
Christopher Bowden, Director, 2025-06-10
G James Coulter, Other, 2024-09-18
Tpg Gp A, Llc, Other, 2024-09-18
Jon Winkelried, Other, 2024-09-18
David Bonderman, Other, 2024-09-18
Ltd Fil, , 2024-09-18
Fmr Llc, , 2024-09-18
Deerfield Mgmt V, L.p., Large Shareholder, Other, 2024-09-17
Deerfield Private Design Fund V, L.p., Large Shareholder, Other, 2024-09-17
E James Flynn, Large Shareholder, Other, 2024-09-17
Deerfield Partners, L.p., Large Shareholder, Other, 2024-09-17
L.p. Mgmt Deerfield, Large Shareholder, Other, 2024-09-17
Deerfield Management Company, L.p. (Series C), Large Shareholder, Other, 2024-09-17
Ltd Biocon, , 2024-09-16
Biocon Pharma Inc., , 2024-09-16
Ivan Hyep, Chief Financial Officer, 2024-09-13
David Raben, Chief Medical Officer, 2024-09-13
Claire Mazumdar, Chief Executive Officer, 2024-09-13
Ryan Cohlhepp, President And Coo, 2024-09-13
Carolyn Ng, , 2024-09-13

Show All Insiders (32)

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Ra	$18.00	152,480	$2,744,640.00	2,652,575	2024-09-16	Filing
Ra	$18.00	1,680,520	$30,249,360.00	4,303,418	2024-09-16	Filing
Flynn Large Shareholder, Other	$18.00	35,000	$630,000.00	897,587	2024-09-17	Filing
Flynn Large Shareholder, Other	$18.00	35,000	$630,000.00	897,587	2024-09-17	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Meisner Officer	$10.43	15,829	$165,096.47	0	2025-06-16	Filing
Meisner	$13.24	30,620	$405,512.91	0	2025-03-14	Filing
Meisner	$12.69	48,526	$615,697.89	30,620	2025-03-14	Filing

News See All

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors.

Keep Reading →

May 27th, 2025 - News